Animal Cell Technology: From Target to Market

This book captures, in the form of concise papers of limited length, the essence of the latest development in those fields of animal cell technology. We hope that it will become a useful resource of the most up to date information in Animal Cell Technology, at least until the next meeting in May 2003 in Spain. Elisabeth Lindner-Olsson Nathalie Chatzissavidou Elke Lullau Acknowledgements This meeting would not have been possible without the help of a large number of people, some of whom you will find mentioned below. In addition to the Organizing Committee and the Scientific Committee, Mrs Eva Ljung kvist and Mrs Ewa Engstrom of SKD Konferensservice have been most important to us. They have had to bear with us, scientists with specific demands for everything. Mrs Ewa Engstrom has also, together with Dr Bjorn Lundgren, organized the trade fare and the fund raising. Mr Henrik Levin at SKD has coordinated the distribution of all confirmation letters for oral presentations and posters as well as the coordination of the manuscripts for the proceedings. We would also like to thank Micael Worbin at TylOsand for local coordination. We have just had a stimulating, pleasant and enriching ESACT 2001 meeting. Your participation was a success and we feel privileged and honored that you decided to come to TylOsand.

Klappentext

This book is the lasting product, a resource of up-to-date information in the scientific literature for the field of animal cell technology, as it was presented during a pleasant and stimulating meeting in Tylösand, Sweden, in June 2001. The title of the meeting, From Target to Market, indicates the usefulness of Animal Cell Technology during all steps in the pharmaceutical development process. Following the biotech products reaching the market, it shows an upward trend in the contribution of biotech products to total New Molecular Entity output in the nineties, which continued until 1996 when biotech represented 25% of the annual output. Since then the proportion has been decreasing. A perceived hurdle from a market perspective is that a protein per definition is biodegradable and thus requires intravenous, or for some drugs subcutaneous administration. New promising administration technologies such as pulmonary delivery were highlighted at this meeting. The emphasis on project selection prior to entry in the development phase has triggered a portfolio management using more extensive preclinical data before a development decision is taken. Animal cells have become a very important tool in the drug discovery process. The next generation of products will evolve from applications such as gene therapy, novel vaccines, cell therapy, and gene regulation. Animal cell technology has a major role to play in the post-sequence era.

Zusammenfassung
Proceedings of the 17th ESACT Meeting June 10-14, 2001, Tylösand, Sweden

Inhalt
17th ESACT Meeting Committees. ESACT Executive Committee. Sponsors. Companies Participating in the Trade Exhibition. List of Participants. Introduction - From Target to Market. Acknowledgements. I. Identification of Drugs and Drug Targets. II. Expression Systems for Target and Drug Production. III. Cell Physiology and Metabolism. IV. Process Technology. V. Changes in Regulatory Environment. VI. New Technologies for Administration of Cell Derived Proteins. VII. Novel Prophylactic and Therapeutic Approaches Based on Animal Cells or Nucleic Acids. Author Index. Subject Index.